Biocon has become the latest Indian company to partner with a Chinese firm to enter the country’s fast-growing pharmaceutical market. The company has signed a license-and-supply deal with China Medical System Holdings Ltd, known as CMS, to sell three generic formulation products in the country. Biocon says opportunities from the fast-liberalizing Chinese drug market could be an important driver of future profit growth.
The total addressable market size is about $800m for the three products, Biocon said, citing IQVIA data. The company did...
